オプションチェーンは、Kewaunee Scientificの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Kewaunee Scientificの市場センチメントを評価します。.

Kewaunee Scientific (NASDAQ:KEQU) 株価情報, オプションチェーン

Kewaunee Scientific

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific Corp

It was reported on April 14, that DAVID THOMAS HULL III, President at Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) executed a significant insider sell, according to an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000055529/000165707025000006//Archives/edgar/data/55529/000165707025000006/0001657070-25-000006-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that III sold 1,844 shares of Kewaunee Scientific. The total transaction amounted to $59,819. 
At Tuesday morning, Kewaunee Scientific shares are down by 0.78%, trading at $31.9.
<h3>About Kewaunee Scientific</h3>
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
<h3>Financial Milestones: Kewaunee Scientific's Journey</h3>
Revenue Growth: Kewaunee Scientific's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 43.59%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 27.36%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Kewaunee Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.47.
</li>
</ul>
Debt Management: Kewaunee Scientific's debt-to-equity ratio stands notably higher than the industry average, reaching 0.86. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Kewaunee Scientific's P/E ratio of 5.41 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.43, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 8.62, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055529">Check Out The Full List Of Kewaunee Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

KEQU

DAVID THOMAS HULL III Implements A Sell Strategy: Offloads $59K In Kewaunee Scientific Stock

A substantial insider sell was reported on April 11, by Donald T. Gardner III, Chief Financial Officer at Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>), based on the recent SEC filing.
What Happened: III's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000055529/000177505225000006//Archives/edgar/data/55529/000177505225000006/0001775052-25-000006-index.htm">U.S. Securities and Exchange Commission</a> on Friday unveiled the sale of 4,000 shares of Kewaunee Scientific. The total transaction value is $148,427.
At Friday morning, Kewaunee Scientific shares are down by 1.3%, trading at $34.1.
<h3>Unveiling the Story Behind Kewaunee Scientific</h3>
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
<h3>Financial Milestones: Kewaunee Scientific's Journey</h3>
Revenue Growth: Over the 3 months period, Kewaunee Scientific showcased positive performance, achieving a revenue growth rate of 43.59% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 27.36%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Kewaunee Scientific's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.47.
</li>
</ul>
Debt Management: Kewaunee Scientific's debt-to-equity ratio surpasses industry norms, standing at 0.86. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 5.82 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.47, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 9.05 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055529">Check Out The Full List Of Kewaunee Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Kewaunee Scientific Chief Financial Officer Sold $148K In Company Stock

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock increased by 165.7% to $9.38 during Monday's pre-market session. The company's market cap stands at $5.1 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock increased by 37.28% to $9.5. The market value of their outstanding shares is at $889.3 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares moved upwards by 35.31% to $1.59. The market value of their outstanding shares is at $3.0 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 26.07% to $4.5. The market value of their outstanding shares is at $165.9 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock moved upwards by 19.98% to $0.81. The company's market cap stands at $51.3 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) shares increased by 18.63% to $0.81. The company's market cap stands at $65.2 million. As per the press release, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 37.0% to $0.15 during Monday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares decreased by 29.45% to $13.01. The market value of their outstanding shares is at $466.6 million. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) stock declined by 22.45% to $6.46. The company's market cap stands at $422.2 million. </li>
<li>Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) shares decreased by 21.48% to $28.01. The market value of their outstanding shares is at $79.9 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 20.64% to $0.31. The company's market cap stands at $2.2 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) stock fell 20.64% to $0.5. The company's market cap stands at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

CBLL

CNTB

GYRE

IMAB

MOLN

PTIX

QNRX

THAR

12 Health Care Stocks Moving In Monday's Pre-Market Session

On March 12, 2025, the Board of Directors of Kewaunee Scientific amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023.&nbsp;
The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended, which does not have a specified expiration date.&nbsp;
The Program, as of the end of day March 12, 2025 and prior to this amendment, still had 11,176 shares authorized for repurchase which remain authorized for repurchase and are unaffected by this amendment.

Buybacks

Kewaunee Scientific Amends Share Repurchase Program, Authorizing Up To An Additional 100,000 Shares

Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) reported $67.17 million in sales this quarter. This is a 43.59 percent increase over sales of $46.78 million the same period last year.

Earnings

Kewaunee Scientific Q3 Sales $67.17M Up From $46.78M YoY

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

AMRN

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

IRBT

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NKTR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

DAVID THOMAS HULL III, President at Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>), executed a substantial insider sell on January 13, according to an SEC filing.
What Happened: III's decision to sell 1,368 shares of Kewaunee Scientific was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000055529/000165707025000002//Archives/edgar/data/55529/000165707025000002/0001657070-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the sale is $82,189.
In the Tuesday's morning session, Kewaunee Scientific's shares are currently trading at $61.8, experiencing a up of 11.96%.
<h3>About Kewaunee Scientific</h3>
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
<h3>Understanding the Numbers: Kewaunee Scientific's Finances</h3>
Revenue Challenges: Kewaunee Scientific's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -5.3%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 29.21%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.05, Kewaunee Scientific showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 8.71 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.82, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Kewaunee Scientific's EV/EBITDA ratio, lower than industry averages at 8.59, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055529">Check Out The Full List Of Kewaunee Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVID THOMAS HULL III Implements A Sell Strategy: Offloads $82K In Kewaunee Scientific Stock

Making a noteworthy insider sell on January 13, Donald T. Gardner III, Chief Financial Officer at Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>), is reported in the latest SEC filing.
What Happened: III opted to sell 1,257 shares of Kewaunee Scientific, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000055529/000177505225000002//Archives/edgar/data/55529/000177505225000002/0001775052-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The transaction's total worth stands at $74,489.
The latest market snapshot at Tuesday morning reveals Kewaunee Scientific shares up by 11.96%, trading at $61.8.
<h3>Unveiling the Story Behind Kewaunee Scientific</h3>
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
<h3>A Deep Dive into Kewaunee Scientific's Financials</h3>
Revenue Growth: Kewaunee Scientific's revenue growth over a period of 3 months has faced challenges. As of 31 October, 2024, the company experienced a revenue decline of approximately -5.3%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 29.21%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Kewaunee Scientific's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.05.
</li>
</ul>
Debt Management: Kewaunee Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 8.71 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.82 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 8.59, Kewaunee Scientific could be considered undervalued.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055529">Check Out The Full List Of Kewaunee Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chief Financial Officer Of Kewaunee Scientific Sold $74K In Stock

On December 26, a recent SEC filing unveiled that Donald T. Gardner III, Chief Financial Officer at Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) made an insider sell.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000055529/000177505224000006//Archives/edgar/data/55529/000177505224000006/0001775052-24-000006-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that III sold 2,049 shares of Kewaunee Scientific. The total transaction amounted to $119,236. 
Tracking the Friday's morning session, Kewaunee Scientific shares are trading at $60.3, showing a down of 5.22%.
<h3>Get to Know Kewaunee Scientific Better</h3>
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
<h3>Understanding the Numbers: Kewaunee Scientific's Finances</h3>
Revenue Challenges: Kewaunee Scientific's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -5.3%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 29.21%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.05, Kewaunee Scientific showcases strong earnings per share.
</li>
</ul>
Debt Management: Kewaunee Scientific's debt-to-equity ratio is below the industry average at 0.14, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: Kewaunee Scientific's P/E ratio of 10.03 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.95 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Kewaunee Scientific's EV/EBITDA ratio at 10.06 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000055529">Check Out The Full List Of Kewaunee Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Transaction: Donald T. Gardner III Sells $119K Worth Of Kewaunee Scientific Shares

WIIM

Kewaunee Scientific shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.

Kewaunee Scientific Q2 EPS $1.01 Up From $0.93 YoY; Revenue $47.764M Down From $50.436M YoY

<h3>Companies Reporting Before The Bell</h3>
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $98.70 million. 
• REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is expected to report quarterly earnings at $0.49 per share on revenue of $603.33 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $4.72 billion. 
• Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) is expected to report quarterly loss at $0.04 per share on revenue of $87.42 million. 
• Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $266.36 million. 
• Photronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAB#NASDAQ">PLAB</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $218.00 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Nordson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) is projected to report quarterly earnings at $2.59 per share on revenue of $736.79 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $316.83 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is estimated to report quarterly earnings at $4.66 per share on revenue of $5.54 billion. 
• Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $13.05 million. 
• 17 Education &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YQ#NASDAQ">YQ</a>) is estimated to report earnings for its third quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is estimated to report earnings for its second quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGNT

CSBR

NDSN

PLAB

REVG

Earnings Scheduled For December 11, 2024

Kewaunee Scientific shares are trading higher. The company announced the acquisition of Nu Aire for $55 million.

Contracts

Kewaunee Scientific Corporation Announced Its Acquisition Of Nu Aire for $55M

Kewaunee Scientific Q1 Sales $48.39M Down From $49.84M YoY

Kewaunee Scientific shares are trading higher following q4 earnings.

Kewaunee Scientific Q4 Adj EPS $1.55 Up From $0.34 YoY

Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) reported quarterly earnings of $3.71 per share. This is a 991.18 percent increase over earnings of $0.34 per share from the same period last year. The company reported $56.70 million in sales this quarter. This is a 5.03 percent increase over sales of $53.99 million the same period last year.

Kewaunee Scientific Q4 EPS $3.71 Up From $0.34 YoY, Sales $56.70M Up From $53.99M YoY

Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) reported quarterly earnings of $0.85 per share. This is a 240 percent increase over earnings of $0.25 per share from the same period last year. The company reported $46.78 million in sales this quarter. This is a 23.09 percent decrease over sales of $60.82 million the same period last year.

Kewaunee Scientific Q3 EPS $0.85 Up From $0.25 YoY, Sales $46.78M Down From $60.82M YoY

Press Releases

Kewaunee Scientific to Report Results for First Quarter Fiscal Year 2025

Kewaunee Scientific Corporation Announces Attendance at the 2024 Arablab Live Tradeshow and Conference

Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2025

Kaskela Law LLC Announces Shareholder Investigation of Kewaunee Scientific Corp. (NASDAQ: KEQU) and Encourages Investors to Contact the Firm

Kewaunee Scientific Corporation Completes Acquisition of Nu Aire

Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2025

Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

Kewaunee Scientific Announces Amendment to Share Repurchase Program

Accuray

HeartBeam

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CytoSorbents

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Kewaunee Scientific

Kewaunee Scientific (KEQU) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル